{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T23:08:59Z","timestamp":1783897739470,"version":"3.55.0"},"reference-count":27,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background<\/jats:bold>\n                    : Although vast clinical evidence supports the oxidative CVD hypothesis, little is known on the effects of statins on LDL\/HDL oxidative functionality. Therefore, the aim of this study was to evaluate the antioxidative effects of rosuvastatin by monitoring the susceptibility of LDL to oxidation and the antioxidative HDL potential in low-to-moderate CV risk subjects.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods<\/jats:bold>\n                    : 40 adult ambulatory patients (aged 53.8\u00b110.9 years, 27 women and 13 men) were included in the study. Data was collected from patients\u2019 records, physical examination, and blood sampling. Subjects were prescribed rosuvastatin at 20mg\/day. Traditional risk-factors\/indicators, lipid parameters, inflammatory\/immune markers, LDL susceptibility to oxidation and HDL antioxidative potential were monitored and statistically analyzed with t-test, Chi-square test, one-way ANOVA, Mann-Whitney, and Kruskal-Wallis tests. Multivariate logistic regression analyses were made. Results were considered significant when p\u22640.05.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    : 67% of the patients showed lower susceptibility of LDL to oxidation after rosuvastatin treatment (p=0.03), with no significant effect on baseline LDL oxidation and lag time. All three LDL oxidative indices were seen to be dependent on the subjects\u2019 lipid profile, hemoglobin levels and the IL-1\u03b1 and IL-8 pro-inflammatory marker levels. 53% of the patients showed higher HDL antioxidative capacity after treatment, but without statistical significance (p=0.07). Increased antioxidative potential of HDL with rosuvastatin treatment was more likely in males (OR=9.350; p=0.010), and subjects achieving lower post-treatment CV relative risk levels (higher CV risk reduction) (OR=0.338; p=0.027).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions<\/jats:bold>\n                    : This study suggests the need of a comprehensive approach when investigating oxidative stress and LDL\/HDL functions, especially in low-to-moderate CVD risk subjects.\n                  <\/jats:p>","DOI":"10.2478\/prilozi-2022-0007","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T03:41:27Z","timestamp":1650598887000},"page":"65-75","source":"Crossref","is-referenced-by-count":2,"title":["Antioxidative Effects of Rosuvastatin in Low-to-Moderate Cardiovascular Risk Subjects"],"prefix":"10.2478","volume":"43","author":[{"given":"Ana","family":"Vavlukis","sequence":"first","affiliation":[{"name":"Ss. Cyril and Methodius University in Skopje , Faculty of Pharmacy , Vodnjanska Str. No. 17, 1000 Skopje, RN Macedonia"},{"name":"Cardiovascular ICCC-Program, Research Institute Hospital de la Santa Creu i Sant Pau , IIB-Sant Pau , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Vavlukis","sequence":"additional","affiliation":[{"name":"Ss. Cyril and Methodius University in Skopje , Faculty of Medicine , 50th Division No. 6, 1000 Skopje, RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Mladenovska","sequence":"additional","affiliation":[{"name":"Ss. Cyril and Methodius University in Skopje , Faculty of Pharmacy , Vodnjanska Str. No. 17, 1000 Skopje, RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandar","family":"Dimovski","sequence":"additional","affiliation":[{"name":"Ss. Cyril and Methodius University in Skopje , Faculty of Pharmacy , Vodnjanska Str. No. 17, 1000 Skopje, RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat\u00e0lia","family":"Mu\u00f1oz-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Cardiovascular ICCC-Program, Research Institute Hospital de la Santa Creu i Sant Pau , IIB-Sant Pau , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"de Santisteban Villaplana","sequence":"additional","affiliation":[{"name":"Cardiovascular ICCC-Program, Research Institute Hospital de la Santa Creu i Sant Pau , IIB-Sant Pau , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Padro","sequence":"additional","affiliation":[{"name":"Cardiovascular ICCC-Program, Research Institute Hospital de la Santa Creu i Sant Pau , IIB-Sant Pau , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Badimon","sequence":"additional","affiliation":[{"name":"Cardiovascular ICCC-Program, Research Institute Hospital de la Santa Creu i Sant Pau , IIB-Sant Pau , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"key":"2026071214254018065_j_prilozi-2022-0007_ref_001","doi-asserted-by":"crossref","unstructured":"1. Marchio P, Guerra-Ojeda S, Vila JM, et al. Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation. Oxidative Medicine and Cellular Longevity. 2019; Article ID: 8563845.10.1155\/2019\/8563845663648231354915","DOI":"10.1155\/2019\/8563845"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_002","doi-asserted-by":"crossref","unstructured":"2. Steven S, Frenis K, Oelze M, et al. Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease. Oxid Med Cell Longev. 2019; 2019: 7092151.10.1155\/2019\/7092151661239931341533","DOI":"10.1155\/2019\/7092151"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_003","doi-asserted-by":"crossref","unstructured":"3. Leiva \u0415, Wehinger S, Guzm\u00e1n L, et al. Role of Oxidized LDL in Atherosclerosis. Hypercholesterolemia. 2015 September; Sekar Ashok Kumar, IntechOpen. Available from: https:\/\/www.intechopen.com\/books\/hypercholesterolemia\/role-of-oxidized-ldl-in-atherosclerosis.10.5772\/59375","DOI":"10.5772\/59375"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_004","doi-asserted-by":"crossref","unstructured":"4. Trpkovic A, Resanovic I, Stanimirovic J, et al. Oxidized low-density lipoprotein as a biomarker of cardiovascular disease. Crit Rev Clin Lab Sci. 2015; 52(2): 70\u201385.10.3109\/10408363.2014.99206325537066","DOI":"10.3109\/10408363.2014.992063"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_005","doi-asserted-by":"crossref","unstructured":"5. Yusoff WNW, Bakar NAA, Muid S, et al. Anti-oxidant activity of HDL using different in vitro assays. Journal of fundamental and applied sciences. 2017; 9(6S): 298\u2013315.10.4314\/jfas.v9i6s.24","DOI":"10.4314\/jfas.v9i6s.24"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_006","doi-asserted-by":"crossref","unstructured":"6. Ali KM, Wonnerth A, Huber K, et al. Cardiovascular disease risk reduction by raising HDL cholesterol \u2013 current therapies and future opportunities. Br J Pharmacol. 2012; 167(6): 1177\u20131194.10.1111\/j.1476-5381.2012.02081.x350498622725625","DOI":"10.1111\/j.1476-5381.2012.02081.x"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_007","doi-asserted-by":"crossref","unstructured":"7. Gao S, Liu J. Association between circulating oxidized low-density lipoprotein and atherosclerotic cardiovascular disease. Chronic Dis Transl Med. 2017; 3(2): 89\u201394.10.1016\/j.cdtm.2017.02.008562769829063061","DOI":"10.1016\/j.cdtm.2017.02.008"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_008","doi-asserted-by":"crossref","unstructured":"8. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955; 34(9): 1345\u201353.10.1172\/JCI10318243870513252080","DOI":"10.1172\/JCI103182"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_009","doi-asserted-by":"crossref","unstructured":"9. de Juan-Franco E, Perez A, Ribas V, et al. Standardization of a method to evaluate the antioxidant capacity of high-density lipoproteins. Int J Biomed Sci. 2009; 5(4): 402\u201310.","DOI":"10.59566\/IJBS.2009.5402"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_010","doi-asserted-by":"crossref","unstructured":"10. Esterbauer H, Striegl G, Puhl H, et al. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun. 1989; 6(1): 67\u201375.10.3109\/107157689090734292722022","DOI":"10.3109\/10715768909073429"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_011","doi-asserted-by":"crossref","unstructured":"11. Alfaddagh A, Martin SS, Leucker TM, et al. Inflammation and cardiovascular disease: From mechanisms to therapeutics. American Journal of Preventive Cardiology. 2020; 4: 100130.10.1016\/j.ajpc.2020.100130831562834327481","DOI":"10.1016\/j.ajpc.2020.100130"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_012","unstructured":"12. Calfee CS, Delucchi KL, Sinha P, et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med. 2018; 6(9): 691\u2013698.10.1016\/S2213-2600(18)30177-2"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_013","doi-asserted-by":"crossref","unstructured":"13. Karmaus PWF, Shi M, Perl S, et al. Effects of rosuvastatin on the immune system in healthy volunteers with normal serum cholesterol. JCI Insight. 2019; 4(21): e131530.10.1172\/jci.insight.131530694877331573980","DOI":"10.1172\/jci.insight.131530"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_014","doi-asserted-by":"crossref","unstructured":"14. Ivanova EA, Myasoedova VA, Melnichenko AA, et al. Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases. Oxid Med Cell Longev. 2017; 2017: 1273042.10.1155\/2017\/1273042544112628572872","DOI":"10.1155\/2017\/1273042"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_015","doi-asserted-by":"crossref","unstructured":"15. Nezami N, Argani H, Safa J, et al. Lovastatin enhances paraoxonase anzyme activity and quells low-density lipoprotein susceptibility to oxidation in type 2 diabetic nephropathy. Clinical Biochemistry. 2011; 44(2): 165\u2013170.10.1016\/j.clinbiochem.2010.10.00620970413","DOI":"10.1016\/j.clinbiochem.2010.10.006"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_016","doi-asserted-by":"crossref","unstructured":"16. Thallinger C, Urbauer E, Lackner E, et al. The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients. Int J Clin Pharmacol Ther. 2005; 43(12): 551\u20137.10.5414\/CPP43551","DOI":"10.5414\/CPP43551"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_017","doi-asserted-by":"crossref","unstructured":"17. Portal VL, Moriguchi EH, Vieria JL, et al. Comparison of the effect of two HMG CoA reductase inhibitors on LDL susceptibility to oxidation. Arquivos Brasileiros de Cardiologia. 2003; 80(2): 156\u2013161.10.1590\/S0066-782X2003000200004","DOI":"10.1590\/S0066-782X2003000200004"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_018","doi-asserted-by":"crossref","unstructured":"18. Pirillo A, Catapano AL. Pitavastatin and HDL: Effects on plasma levels and function(s). Atheroscler Suppl. 2017; 27:e1-e9.10.1016\/j.atherosclerosissup.2017.05.00128716185","DOI":"10.1016\/j.atherosclerosissup.2017.05.001"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_019","doi-asserted-by":"crossref","unstructured":"19. Triolo M, Annema W, de Boer JF, et al. Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes. Eur J Clin Invest. 2014; 44(3): 240\u20138.10.1111\/eci.1222624325778","DOI":"10.1111\/eci.12226"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_020","doi-asserted-by":"crossref","unstructured":"20. Parthasarathy S, Raghavamenon A, Garelnabi MO, et al. Oxidized low-density lipoprotein. Methods Mol Biol. 2010; 610: 403\u2013417.10.1007\/978-1-60327-029-8_24331535120013192","DOI":"10.1007\/978-1-60327-029-8_24"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_021","doi-asserted-by":"crossref","unstructured":"21. Fessler MB, Rose K, Zhang Y, et al. Relationship between serum cholesterol and indices of erythrocytes and platelets in the US population. J Lipid Res. 2013; 54(11): 3177\u20133188.10.1194\/jlr.P037614379362223999863","DOI":"10.1194\/jlr.P037614"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_022","doi-asserted-by":"crossref","unstructured":"22. Wang X, Yang L, Liu Y, et al. Oxidized low-density lipoprotein (Ox-LDL) impacts on erythrocyte viscoelasticity and its molecular mechanism. Journal of Biomechanics. 2009; 42(14): 2394\u20132399.10.1016\/j.jbiomech.2009.05.02619747680","DOI":"10.1016\/j.jbiomech.2009.05.026"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_023","doi-asserted-by":"crossref","unstructured":"23. Rhoads JP, Major AS. How Oxidized Low-Density Lipoprotein Activates Inflammatory Responses. Crit Rev Immunol. 2018; 38(4): 333\u2013342.10.1615\/CritRevImmunol.2018026483652711030806246","DOI":"10.1615\/CritRevImmunol.2018026483"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_024","doi-asserted-by":"crossref","unstructured":"24. Pirillo A, Norata GD, Catapano AL. LOX-1, Ox-LDL and Atherosclerosis. Mediators of Inflammation. 2013; 152786.10.1155\/2013\/152786372331823935243","DOI":"10.1155\/2013\/152786"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_025","doi-asserted-by":"crossref","unstructured":"25. McCarthy DA, Ranganathan A, Subbaram S, et al. Redox-control of the alarmin, Interleukin-1\u03b1. Redox Biol. 2013; 1(1): 218\u2013225.10.1016\/j.redox.2013.03.001375769324024155","DOI":"10.1016\/j.redox.2013.03.001"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_026","doi-asserted-by":"crossref","unstructured":"26. Liu T, Zhang L, Joo D, et al. NF-kB signaling in inflammation. Signal Transduction and Targeted Therapy. 2017; 2: 17023.10.1038\/sigtrans.2017.23566163329158945","DOI":"10.1038\/sigtrans.2017.23"},{"key":"2026071214254018065_j_prilozi-2022-0007_ref_027","unstructured":"27. Tao J, Zhang D, Zhang D, et al. Effect of sodium ferulate on IL-8 expression induced by Ox-LDL in human umbilical vein endothelial cells. Biomedical Research. 2017; 28(5)."}],"container-title":["PRILOZI"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/prilozi-2022-0007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T23:01:51Z","timestamp":1783897311000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/prilozi-2022-0007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,4,22]]},"published-print":{"date-parts":[[2022,3,1]]}},"alternative-id":["10.2478\/prilozi-2022-0007"],"URL":"https:\/\/doi.org\/10.2478\/prilozi-2022-0007","relation":{},"ISSN":["1857-8985"],"issn-type":[{"value":"1857-8985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]}}}